Literature DB >> 9331280

Increased plasma levels of substance P in vernal keratoconjunctivitis.

A Lambiase1, S Bonini, A Micera, P Tirassa, L Magrini, S Bonini, L Aloe.   

Abstract

PURPOSE: The increase of nerve growth factor (NGF) plasma levels in vernal keratoconjunctivitis (VKC) patients has been demonstrated previously. Results of numerous studies in vitro and in vivo have shown that NGF modulates the synthesis of substance P (SP), a neuropeptide involved in the pathogenesis of human allergic diseases. In this study the involvement of SP in this allergic conjunctivitis is investigated, along with its relationship with NGF and other systemic and local markers of VKC.
METHODS: Competitive radioimmunoassays were used to detect the levels of SP in plasma, the levels of eosinophil cationic protein, and the total and specific immunoglobulin E in the serum of 11 patients with VKC and in 11 healthy matched controls. Plasma levels of nerve growth factor (NGF) were measured in all VKC patients and controls using an immunoenzymatic assay. Histologic evaluation was performed in tarsal and bulbar conjunctival specimens obtained in biopsies from 8 VKC patients and 4 control subjects.
RESULTS: Patients with VKC show a significant increase of SP and NGF plasma levels (P < 0.003 and P < 0.001, respectively), and an increase of eosinophil cationic protein and immunoglobulin E levels in the serum (P < 0.001 and P < 0.002, respectively). Mast cells, eosinophils, and lymphocytes were also significantly increased in the conjunctiva of VKC patients. Interestingly enough, VKC patients with the highest NGF plasma levels also showed the highest SP levels.
CONCLUSIONS: The data show the involvement of SP in VKC and suggest that SP with NGF could modulate the allergic response in this disease, probably through an interaction with inflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9331280

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  9 in total

Review 1.  Ocular mast cells. Characterization in normal and disease states.

Authors:  E B Cook; J L Stahl; N P Barney; F M Graziano
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

Review 2.  [Ocular allergies].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

Review 3.  The pathogenesis of allergic conjunctivitis.

Authors:  A Keane-Myers
Journal:  Curr Allergy Asthma Rep       Date:  2001-11       Impact factor: 4.806

4.  Morphology and neurochemistry of rabbit iris innervation.

Authors:  Jiucheng He; Haydee E P Bazan
Journal:  Exp Eye Res       Date:  2015-03-07       Impact factor: 3.467

Review 5.  The central role of conjunctival mast cells in the pathogenesis of ocular allergy.

Authors:  Andrea Leonardi
Journal:  Curr Allergy Asthma Rep       Date:  2002-07       Impact factor: 4.919

6.  Tear levels of neuropeptides increase after specific allergen challenge in allergic conjunctivitis.

Authors:  Marta Sacchetti; Alessandra Micera; Alessandro Lambiase; Stefania Speranza; Flavio Mantelli; Girolamo Petrachi; Sergio Bonini; Stefano Bonini
Journal:  Mol Vis       Date:  2011-01-07       Impact factor: 2.367

7.  Quiescent and Active Tear Protein Profiles to Predict Vernal Keratoconjunctivitis Reactivation.

Authors:  Alessandra Micera; Antonio Di Zazzo; Graziana Esposito; Roberto Sgrulletta; Virginia L Calder; Stefano Bonini
Journal:  Biomed Res Int       Date:  2016-02-17       Impact factor: 3.411

Review 8.  Potential Biomarkers for Allergic Conjunctival Diseases.

Authors:  Neeta Roy; Shir Levanon; Penny A Asbell
Journal:  Eye Contact Lens       Date:  2020-03       Impact factor: 3.152

9.  Long Term Outcomes of Surgical Excision of Giant Papillae with Mitomycin C and Amniotic Membrane Transplantation in the Treatment of Refractory Palpebral Vernal Keratoconjunctivitis.

Authors:  Moushmi Patil; Jodhbir S Mehta
Journal:  Medicina (Kaunas)       Date:  2021-12-23       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.